GS 986

Drug Profile

GS 986

Alternative Names: GS 9620 analogue; GS-986

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Beth Israel Deaconess Medical Center; Gilead Sciences
  • Class Pteridines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 13 Feb 2017 Preclinical data in HIV-1 infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 25 Feb 2016 Preclinical data from simian immunodeficiency virus infected rhesus macaques released by Gilead
  • 25 Feb 2015 Preclinical trials in HIV infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top